Search Results - "REMENAR, Eva"

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer by Vermorken, Jan B, Mesia, Ricard, Rivera, Fernando, Remenar, Eva, Kawecki, Andrzej, Rottey, Sylvie, Erfan, Jozsef, Zabolotnyy, Dmytro, Kienzer, Heinz-Roland, Cupissol, Didier, Peyrade, Frederic, Benasso, Marco, Vynnychenko, Ihor, De Raucourt, Dominique, Bokemeyer, Carsten, Schueler, Armin, Amellal, Nadia, Hitt, Ricardo

“…This randomized trial of the treatment of advanced head and neck cancer tested the efficacy of adding cetuximab, an antibody against the epidermal growth…”
Get full text

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study by Forster, Martin D., Dillon, Magnus T., Kocsis, Judit, Remenár, Éva, Pajkos, Gabor, Rolland, Frederic, Greenberg, Jonathan, Harrington, Kevin J.

“…The fully human monoclonal antibody patritumab blocks HER3 activation, a resistance mechanism to cetuximab, induced by heregulin (HRG). A phase Ib study in…”
Get full text

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer by Vermorken, Jan B, Remenar, Eva, van Herpen, Carla, Gorlia, Thierry, Mesia, Ricard, Degardin, Marian, Stewart, John S, Jelic, Svetislav, Betka, Jan, Preiss, Joachim H, van den Weyngaert, Danielle, Awada, Ahmad, Cupissol, Didier, Kienzer, Heinz R, Rey, Augustin, Desaunois, Isabelle, Bernier, Jacques, Lefebvre, Jean-Louis

“…This trial of therapies for unresectable advanced head and neck cancer showed that induction chemotherapy (given before radiotherapy) with a combination of…”
Get full text

Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1 by Soulières, Denis, Licitra, Lisa, Mesía, Ricard, Remenár, Éva, Li, Shau-Hsuan, Karpenko, Andrey, Chol, Marie, Wang, Ying A, Solovieff, Nadia, Bourdeau, Laurence, Sellami, Dalila, Faivre, Sandrine

“…The preplanned exploratory analysis of the BERIL-1 trial presented here aimed to identify biomarkers of response to the combination of buparlisib and…”
Get full text

Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients by Szturz, Petr, Vinches, Marie, Remenár, Éva, van Herpen, Carla M.L., Abdeddaim, Cyril, Stewart, John S., Fortpied, Catherine, Vermorken, Jan B.

“…In the TAX 323 (EORTC 24971) phase III trial enrolling patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck…”
Get full text

Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab by Ladányi, Andrea, Kapuvári, Bence, Papp, Eszter, Tóth, Erika, Lövey, József, Horváth, Katalin, Gődény, Mária, Remenár, Éva

“…Background The aim of this study was to determine whether tumor‐associated immune cells may predict response to therapy and disease outcome in head and neck…”
Get full text

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer by Cserepes, Mihály, Nelhűbel, Györgyi A, Meilinger-Dobra, Mónika, Herczeg, Adrienn, Türk, Dóra, Hegedűs, Zita, Svajda, Laura, Rásó, Erzsébet, Ladányi, Andrea, Csikó, Kristóf György, Kenessey, István, Szöőr, Árpád, Vereb, György, Remenár, Éva, Tóvári, József

“…Head and neck squamous cell carcinomas (HNSCCs) are among the most abundant malignancies worldwide. Patients with recurrent/metastatic disease undergo…”
Get full text

Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis by Gődény, Mária, Lengyel, Zsolt, Polony, Gábor, Nagy, Zoltán Takácsi, Léránt, Gergely, Zámbó, Orsolya, Remenár, Éva, Tamás, László, Kásler, Miklós

“…This study aimed to determine the ability of multimodal evaluation with multiparametric 3T-MRI (MPMRI) and positron emission tomography - computed tomography…”
Get full text

Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy by Remenár, Éva, Dóczi, Róbert, Dirner, Anna, Sipos, Anna, Perjési, Anita, Tihanyi, Dóra, Vodicska, Barbara, Lakatos, Dóra, Horváth, Katalin, Kajáry, Kornélia, Schwáb, Richárd, Déri, Júlia, Lengyel, Csongor György, Várkondi, Edit, Vályi-Nagy, István, Peták, István

Get more information

Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial by Vermorken, Jan Baptist, Remenar, Eva, Hitt, Ricardo, Kawecki, Andrzej, Rottey, Sylvie, Knierim, Luise, Schulten, Jeltje, Mesia, Ricard

“…Abstract only…”
Get full text

Mutagen sensitivity of patients with cancer at different sites of the head and neck by Székely, Gábor, Remenár, Éva, Kásler, Miklós, Gundy, Sarolta

“…In the aetiology of head and neck squamous cell carcinoma (HNSCC), smoking and heavy alcohol consumption are the main environmental risk factors. The bleomycin…”
Get full text

Does the bleomycin sensitivity assay express cancer phenotype? by Székely, Gábor, Remenár, Éva, Kásler, Miklós, Gundy, Sarolta

“…The bleomycin (BLM) sensitivity assay has been associated with the measuring of increased risk of individual susceptibility to cancer, when chromatid breaks…”
Get full text

RARβ2 suppression in head and neck squamous cell carcinoma correlates with site, histology and age by OLASZ, Judit, JUHASZ, Aliz, REMENAR, Eva, ENGI, Helga, BAK, Mihaly, CSUKA, Orsolya, KASLER, Miklos

Get full text

Increase of hypophyseal hormone levels in male head and neck cancer patients by Remenár, Eva, Számel, Irén, Budai, Barna, Vincze, Borbála, Gaudi, István, Gundy, Sarolta, Kásler, Miklós

“…Head and neck squamous cell carcinoma (HNSCC) develops in at least 80% of cases in men with a history of smoking and heavy alcohol consumption, still it is…”
Get full text

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study by Burtness, Barbara, Greil, Richard, de Castro, Gilberto, Fuereder, Thorsten, Ngamphaiboon, Nuttapong, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Zhang, Yayan, Gumuscu, Burak, Boyer, Michael, Hughes, Brett, Rischin, Danny, Taylor, Anne, Burian, Martin, Barrios, Carlos Henrique, de Castro Junior, Dalvaro Oliveira, Franke, Fabio Andre, Girotto, Gustavo, Lima, Iane Pinto Figueiredo, Nicolau, Ulisses Ribaldo, Santos, Lucas, Victorino, Ana-Paula, Chua, Neil, Couture, Felix, Hansen, Aaron, Hilton, John, McCarthy, Joy, Soulieres, Denis, Ascui, Rodrigo, Villanueva, Luis, Kral, Zdenek, Prausova, Jana, Vosmik, Milan, Jurgens, Hannes, Putnik, Kadri, Gruenwald, Viktor, Boukovinas, Ioannis, Psyrri, Amanda, Kwong, Dora, Csoszi, Tibor, Horvai, Geza, Landherr, Laszlo, Szota, Judit, Billan, Salem, Nole, Franco, Fujimoto, Yasushi, Hanai, Nobuhiro, Hara, Hiroki, Shimizu, Yasushi, Sugasawa, Masashi, Takahashi, Shunji, Tanaka, Kaoru, Ueda, Tsutomu, Wan Ishak, Wan Zamaniah, Gonzalez Mendoza, Rene, Buter, Jan, Hoeben, Ann, Bratland, Aase, Querol, John, Regala, Eugenio Emmanuel, Villegas, Ellie May, Karpenko, Andrey, Zarubenkov, Oleg, Cohen, Graham, du Toit, Johanna, Jordaan, Christa, Landers, Gregory, Ruff, Paul, Tabane, Neonyana, Brana, Irene, Iglesias Docampo, Lara, Abel, Edvard, Muratidu, Valentina, Nielsen, Niels, Cristina, Valerie, Rothschild, Sacha, Yang, Muh-Hwa, Yeh, Su-Peng, Ngamphaiboon, Nuttapong, Cicin, Irfan, Ekenel, Meltem, Harrington, Kevin, Ali, Haythem, Anderson, Daniel, Bruce, Justine, Halmos, Balazs, Hegde, Upendra, Khan, Saad, Martincic, Danko, McCune, Steven, Misiukiewicz, Krzysztof, Neupane, Prakash, Nunnink, Johannes, O'Malley, Meaghan, Powell, Steven, Redman, Rebecca, Rella, Vincent, Rocha Lima, Chaio, Wong, Stuart

“…Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved…”
Get full text

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy by Zandberg, Dan P., Algazi, Alain P., Jimeno, Antonio, Good, James S., Fayette, Jérôme, Bouganim, Nathaniel, Ready, Neal E., Clement, Paul M., Even, Caroline, Jang, Raymond W., Wong, Stuart, Keilholz, Ulrich, Gilbert, Jill, Fenton, Moon, Braña, Irene, Henry, Stephanie, Remenar, Eva, Papai, Zsuzsanna, Siu, Lillian L., Jarkowski, Anthony, Armstrong, Jon M., Asubonteng, Kobby, Fan, Jean, Melillo, Giovanni, Mesía, Ricard

“…Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses and limited…”
Get full text

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial by Siu, Lillian L, Even, Caroline, Mesía, Ricard, Remenar, Eva, Daste, Amaury, Delord, Jean-Pierre, Krauss, Jürgen, Saba, Nabil F, Nabell, Lisle, Ready, Neal E, Braña, Irene, Kotecki, Nuria, Zandberg, Dan P, Gilbert, Jill, Mehanna, Hisham, Bonomi, Marcelo, Jarkowski, Anthony, Melillo, Giovanni, Armstrong, Jon M, Wildsmith, Sophie, Fayette, Jérôme

“…Dual blockade of programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) may overcome immune checkpoint inhibition. It is…”
Get more information

Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) by Harrington, Kevin J., Forster, Martin David, Le Tourneau, Christophe, Ariza, Jose, Chen, Shuquan, Greenberg, Jonathan, Hirotani, Kenji, Remenar, Eva

“…Abstract only…”
Get full text

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease by Harrington, Kevin, Berrier, Alain, Robinson, Martin, Remenar, Eva, Housset, Martin, de Mendoza, Fernando Hurtado, Fayette, Jérôme, Mehanna, Hisham, El-Hariry, Iman, Compton, Natalie, Franklin, Natalie, Biswas-Baldwin, Nigel, Lau, Mike, Legenne, Philippe, Kumar, Rejnish

“…Abstract Background This randomised Phase II study assessed the activity and safety of concurrent chemoradiotherapy (CRT) and lapatinib followed by maintenance…”
Get full text

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial by Soulières, Denis, Prof, Faivre, Sandrine, Prof, Mesía, Ricard, Prof, Remenár, Éva, Prof, Li, Shau-Hsuan, Prof, Karpenko, Andrey, Prof, Dechaphunkul, Arunee, MD, Ochsenreither, Sebastian, Prof, Kiss, Laura Anna, Prof, Lin, Jin-Ching, Prof, Nagarkar, Raj, Prof, Tamás, László, Prof, Kim, Sung-Bae, Prof, Erfán, Jozsef, Prof, Alyasova, Anna, Prof, Kasper, Stefan, Prof, Barone, Carlo, Prof, Turri, Sabine, MS, Chakravartty, Arunava, PhD, Chol, Marie, PhD, Aimone, Paola, Prof, Hirawat, Samit, Prof, Licitra, Lisa, Prof

“…Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation in squamous cell carcinoma of the head and neck contributes to treatment resistance…”
Get full text